Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

ASPEN investigators, Gavin Cull

Research output: Contribution to journalArticlepeer-review

21 Citations (Web of Science)

Fingerprint

Dive into the research topics of 'Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial'. Together they form a unique fingerprint.

Medicine & Life Sciences